These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 36403342)

  • 1. Precision medicine: Ray of hope in overcoming cancer multidrug resistance.
    Musyuni P; Bai J; Sheikh A; Vasanthan KS; Jain GK; Abourehab MAS; Lather V; Aggarwal G; Kesharwani P; Pandita D
    Drug Resist Updat; 2022 Dec; 65():100889. PubMed ID: 36403342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The multi-factorial nature of clinical multidrug resistance in cancer.
    Assaraf YG; Brozovic A; Gonçalves AC; Jurkovicova D; Linē A; Machuqueiro M; Saponara S; Sarmento-Ribeiro AB; Xavier CPR; Vasconcelos MH
    Drug Resist Updat; 2019 Sep; 46():100645. PubMed ID: 31585396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance.
    Zhang A; Miao K; Sun H; Deng CX
    Int J Biol Sci; 2022; 18(7):3019-3033. PubMed ID: 35541919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The multi-molecular mechanisms of tumor-targeted drug resistance in precision medicine.
    Li X; Li M; Huang M; Lin Q; Fang Q; Liu J; Chen X; Liu L; Zhan X; Shan H; Lu D; Li Q; Li Z; Zhu X
    Biomed Pharmacother; 2022 Jun; 150():113064. PubMed ID: 35658234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
    Bar-Zeev M; Livney YD; Assaraf YG
    Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological strategies for overcoming multidrug resistance.
    Nobili S; Landini I; Giglioni B; Mini E
    Curr Drug Targets; 2006 Jul; 7(7):861-79. PubMed ID: 16842217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surmounting cancer drug resistance: New insights from the perspective of N
    Li B; Jiang J; Assaraf YG; Xiao H; Chen ZS; Huang C
    Drug Resist Updat; 2020 Dec; 53():100720. PubMed ID: 32892147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microfluidic design in single-cell sequencing and application to cancer precision medicine.
    Han X; Xu X; Yang C; Liu G
    Cell Rep Methods; 2023 Sep; 3(9):100591. PubMed ID: 37725985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights into new mechanisms and models of cancer stem cell multidrug resistance.
    Garcia-Mayea Y; Mir C; Masson F; Paciucci R; LLeonart ME
    Semin Cancer Biol; 2020 Feb; 60():166-180. PubMed ID: 31369817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine.
    Van den Bossche V; Zaryouh H; Vara-Messler M; Vignau J; Machiels JP; Wouters A; Schmitz S; Corbet C
    Drug Resist Updat; 2022 Jan; 60():100806. PubMed ID: 35121337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine.
    Bashraheel SS; Domling A; Goda SK
    Biomed Pharmacother; 2020 May; 125():110009. PubMed ID: 32106381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Exploration of Molecular Targets in the Development of New Therapeutics Aimed at Overcoming Multidrug Resistance].
    Nishida S; Tsubaki M
    Yakugaku Zasshi; 2017; 137(2):145-149. PubMed ID: 28154323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors.
    Dallavalle S; Dobričić V; Lazzarato L; Gazzano E; Machuqueiro M; Pajeva I; Tsakovska I; Zidar N; Fruttero R
    Drug Resist Updat; 2020 May; 50():100682. PubMed ID: 32087558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roles of tumor heterogeneity in the development of drug resistance: A call for precision therapy.
    Wu D; Wang DC; Cheng Y; Qian M; Zhang M; Shen Q; Wang X
    Semin Cancer Biol; 2017 Feb; 42():13-19. PubMed ID: 27840278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reconciling environment-mediated metabolic heterogeneity with the oncogene-driven cancer paradigm in precision oncology.
    Vander Linden C; Corbet C
    Semin Cell Dev Biol; 2020 Feb; 98():202-210. PubMed ID: 31103464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Precision oncology: a clinical and patient perspective.
    Lassen UN; Makaroff LE; Stenzinger A; Italiano A; Vassal G; Garcia-Foncillas J; Avouac B
    Future Oncol; 2021 Oct; 17(30):3995-4009. PubMed ID: 34278817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Precision medicine: A major step forward in specific situations, a myth in refractory cancers?].
    Albin N; Mc Leer A; Sakhri L
    Bull Cancer; 2018 Apr; 105(4):375-396. PubMed ID: 29501208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Precision medicine in pediatric oncology.
    Forrest SJ; Geoerger B; Janeway KA
    Curr Opin Pediatr; 2018 Feb; 30(1):17-24. PubMed ID: 29189430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology.
    Tao JJ; Schram AM; Hyman DM
    Annu Rev Med; 2018 Jan; 69():319-331. PubMed ID: 29120700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer genome and tumor microenvironment: Reciprocal crosstalk shapes lung cancer plasticity.
    Mansouri S; Heylmann D; Stiewe T; Kracht M; Savai R
    Elife; 2022 Sep; 11():. PubMed ID: 36074553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.